EPIRUS Biopharmaceuticals, Inc. (EPRSQ)
For informational purposes only. Not financial advice.
EPIRUS Biopharmaceuticals, Inc. (EPRSQ) is a publicly traded company trading at $0.00 with a market cap of 2K. It holds a cautious AI score of 46/100 based on fundamental, technical, and sentiment analysis.
EPIRUS Biopharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing biosimilar therapeutics. The company filed for liquidation under Chapter 7 bankruptcy in 2016.
Company Overview
EPIRUS Biopharmaceuticals aimed to revolutionize treatment for inflammatory diseases and ultra-rare blood disorders through biosimilar development, offering potential cost-effective alternatives, before filing for Chapter 7 liquidation in 2016, ceasing operations and development.
Investment Thesis
Investing in EPRSQ is not advisable due to the company's Chapter 7 liquidation filing in 2016. The company's assets are being liquidated, and there is no ongoing business operation. The potential for return on investment is extremely low. The company's pipeline of biosimilar product candidates, including BOW015, BOW050, BOW070, BOW080, and BOW100, are no longer under development. The company's market capitalization is effectively zero, reflecting its defunct status. Investors should be aware of the high risk associated with investing in companies undergoing liquidation.
Key Highlights
- Lead product candidate BOW015 was a biosimilar version of Remicade (infliximab) targeting inflammatory diseases.
- Pipeline included biosimilars for Humira (adalimumab), Actemra (tocilizumab), Soliris, and SIMPONI.
- Collaborations with Sun Pharmaceutical Industries Ltd., Livzon Mabpharm Inc., and Polpharma S.A.
- Filed for Chapter 7 liquidation on July 25, 2016.
- Market capitalization is $0.00B, reflecting its defunct status.
Competitors
Strengths
- Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.
Weaknesses
- Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.
Catalysts
- Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.
Risks
- Ongoing: Liquidation risk due to Chapter 7 bankruptcy filing.
- Ongoing: No ongoing business operations.
- Ongoing: No potential for future revenue generation.
Growth Opportunities
- Growth opportunity 1: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.
- Growth opportunity 2: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.
- Growth opportunity 3: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.
- Growth opportunity 4: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.
- Growth opportunity 5: Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no growth opportunities associated with the company.
Opportunities
- Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.
Threats
- Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs.
Competitive Advantages
- Not applicable. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. Therefore, there are no competitive advantages associated with the company.
About
Founded in 2011 and headquartered in Boston, Massachusetts, EPIRUS Biopharmaceuticals, Inc. was a biopharmaceutical company dedicated to developing, manufacturing, and commercializing biosimilar therapeutics on a global scale. The company's core strategy revolved around creating biosimilar versions of established biologic drugs, offering potentially more affordable treatment options for a range of diseases. Their lead product candidate was BOW015, a biosimilar version of Remicade (infliximab), targeting inflammatory diseases. The pipeline also included BOW050, a biosimilar of Humira (adalimumab); BOW070, a biosimilar of Actemra (tocilizumab); BOW080, a biosimilar of Soliris; and BOW100, a biosimilar of SIMPONI. These biosimilars were intended to treat a variety of conditions, including rheumatoid arthritis, inflammatory bowel disease, and ultra-rare blood disorders. EPIRUS established strategic collaborations and licensing agreements with companies like Sun Pharmaceutical Industries Ltd., Livzon Mabpharm Inc., and Polpharma S.A. to support its development and commercialization efforts. However, on July 25, 2016, EPIRUS Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court, effectively halting its operations and development programs.
What They Do
- Developed biosimilar therapeutics.
- Aimed to manufacture biosimilar versions of existing biologic drugs.
- Focused on treatments for inflammatory diseases and ultra-rare blood disorders.
- Sought to commercialize biosimilars globally.
- Partnered with other pharmaceutical companies for development and distribution.
- Filed for Chapter 7 liquidation in 2016.
Business Model
- Develop biosimilar versions of branded biologic drugs.
- Out-license or co-develop biosimilars with partners.
- Commercialize biosimilars directly or through partners.
- Generate revenue through product sales and licensing fees.
Industry Context
The biotechnology industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Companies like ALNAQ, ARTH, GNRS, GWHP, and INTP operate in this space. The biosimilar market offers opportunities for companies to develop and commercialize cost-effective alternatives to existing biologic drugs. However, the industry also faces challenges such as patent disputes, regulatory hurdles, and pricing pressures. EPIRUS Biopharmaceuticals aimed to capitalize on the biosimilar market but ultimately failed due to financial constraints, leading to its liquidation.
Key Customers
- Patients suffering from inflammatory diseases.
- Healthcare providers prescribing biologic drugs.
- Hospitals and clinics using biologic treatments.
- Pharmaceutical companies partnering for distribution.
Financials
Chart & Info
Price Chart
EPIRUS Biopharmaceuticals, Inc. (EPRSQ) stock price: $0.00 (-0.00, -99.00%)
Why Bull
- •Recent insider buying suggests those in the know see potential upside, signaling confidence in the company's future prospects.
- •The community is buzzing about potential partnerships, creating a positive sentiment around the stock's growth opportunities.
- •EPRSQ's focus on innovative therapies is gaining traction, positioning them well in a competitive market.
- •Positive community feedback on recent clinical trial updates indicates growing belief in the company's pipeline.
Why Bear
- •The community is expressing concerns about increased competition in EPRSQ's therapeutic area, potentially impacting market share.
- •Recent market volatility is creating uncertainty around smaller biotech stocks like EPRSQ, leading to risk aversion.
- •Some community members are worried about the company's cash burn rate and potential need for further funding.
- •Negative sentiment has emerged in the community regarding recent regulatory hurdles, raising doubts about future approvals.
Latest News
No recent news available for EPRSQ.
Technical Analysis
Rationale
AI-generated technical analysis for EPRSQ including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss EPIRUS Biopharmaceuticals, Inc. (EPRSQ) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for EPRSQ.
Make a Prediction
Set your price target for EPIRUS Biopharmaceuticals, Inc. (EPRSQ), choose a timeframe, and track your prediction accuracy.
Current price: $0.00
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EPRSQ.
Price Targets
Wall Street price target analysis for EPRSQ.
Insider Flow (30d)
No insider trades in the last 30 days.
MoonshotScore
Score Factors
-
Revenue Growth 5/100
Revenue growth data is currently unavailable for this company.
-
Gross Margin 5/100
Gross margin data is currently unavailable for this company.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates EPRSQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Frequently Asked Questions
What does EPIRUS Biopharmaceuticals, Inc. (EPRSQ) do?
EPIRUS Biopharmaceuticals, Inc. was a biopharmaceutical company focused on developing, manufacturing, and commercializing biosimilar therapeutics. Its primary goal was to create more affordable versions of existing biologic drugs, targeting inflammatory diseases and ultra-rare blood disorders. However, the company filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs, and is no longer an active entity.
Is EPRSQ stock a good buy?
No, EPRSQ stock is not a good buy. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, indicating that the company is undergoing asset liquidation and has ceased its business operations. With a market capitalization of $0.00B and no ongoing business, there is virtually no potential for return on investment. Investing in EPRSQ carries an extremely high risk and is not recommended.
What are the risks of investing in EPRSQ?
The primary risk of investing in EPRSQ is the ongoing liquidation process due to the Chapter 7 bankruptcy filing. This means the company's assets are being sold off to pay creditors, and there are no ongoing business operations. There is a high probability of complete loss of investment, and investors should be aware of the significant financial risks involved with investing in a company undergoing liquidation.
What catalysts could move EPRSQ stock?
There are no catalysts that could move EPRSQ stock. EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016, ceasing all operations and development programs. With no ongoing business or active pipeline, there are no potential events or developments that could positively influence the stock price. The company's financial situation makes any positive movement highly improbable.
What is EPRSQ stock price target?
There is no EPRSQ stock price target available. Given that EPIRUS Biopharmaceuticals filed for Chapter 7 liquidation in 2016 and has no ongoing business operations, analysts do not provide price targets for the stock. The company's financial status and liquidation process make it impossible to determine a meaningful price target.
Is EPRSQ a good stock to buy?
Whether EPRSQ is a suitable investment depends on your goals, risk tolerance, and time horizon. Evaluate EPIRUS Biopharmaceuticals, Inc.'s revenue growth, profit margins, debt levels, and valuation relative to peers. This is not financial advice.
What is the EPRSQ MoonshotScore?
The MoonshotScore rates EPRSQ from 0 to 100 across growth potential, financial health, market momentum, and risk factors. Scores above 70 suggest strong potential, 50-70 moderate, and below 50 warrants caution. It is recalculated daily using the latest market data. This score is informational only.
How often is EPRSQ data updated?
EPRSQ prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Company filed for Chapter 7 liquidation in 2016. Information is based on historical data prior to liquidation.